JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Not Recruiting

Trial ID: NCT04429191


This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation.

Official Title

A Phase 1a/b Study to Evaluate the Safety & Tolerability of JSP191 in Combination With a Regimen of Low Dose Radiation & Fludarabine in Subjects With MDS or AML Undergoing Hematopoietic Cell Transplantation (HCT)

Stanford Investigator(s)

Lori Muffly
Lori Muffly

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)


Key Inclusion Criteria:

   - AML/MDS as defined by specific criteria, including but not limited to the following

      1. AML in CR

      2. MDS < 5% BM blasts

      3. MDS 5 - 10% BM blasts

      4. AML not in CR or MDS > 10% BM blasts

   - Patients with human leukocyte antigen (HLA) matched related or unrelated donors

   - Adequate end organ function as defined in study protocol

Key Exclusion Criteria:

   - Patients with any acute or uncontrolled infections

   - Patients receiving any other investigational agents

   - Patients with active non-hematologic malignancy

   - Prior allogeneic hematologic cell transplantation


biological: Humanized anti-CD117 Monoclonal Antibody (JSP191)

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Michelle Chin

New Trial Alerts